The US Food and Drug Administration (FDA) has granted 510(k) approval to Accuray’s new CyberKnife M6 series, designed for treating large and complex tumors.
Designed specifically for use in stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments, the system features an InCise multileaf collimator and can be moved around the patient by a robot in 3D to deliver shaped beams to the target in a non-isocentric, non-coplanar manner.
University of Pittsburgh School of Medicine radiation oncology, otolaryngology, head and neck surgery professor and vice-chairman Dr Dwight Heron said the InCise collimator is designed to emit a single, shaped radiation beam matching the exact contour of a tumor, thus minimising the amount of radiation to the surrounding tissues and reducing the treatment time.
"Now many targets previously unsuited for SRS/SBRT can be treated more quickly and effectively than before," Heron said.
Accuray president and chief executive officer Joshua Levine said; "Accuray developed the CyberKnife M6 Series to provide the radiation oncology community with a personalized, patient-focused treatment that delivers unmatched clinical capabilities and the ability to treat more patients with unprecedented levels of precision and efficiency."
In addition, the CyberKnife M6 systems when used with the CyberKnife’s Synchrony system can track tumors as they move and automatically correct for their movement throughout treatment.
Fox Chase Cancer Centre radiation oncology department vice chairman radiation physics director Dr Charlie Ma said; "The addition of the MLC, combined with the CyberKnife’s ability to deliver treatment from hundreds of angles while tracking and correcting for motion, will give us the flexibility to deliver the most accurate patient-specific and tailored dose distributions and allows a broader range of patients to benefit from highly efficient and effective treatments."